Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel

Core Insights - Soligenix, Inc. announced extended results from its Phase 2a trial of SGX302 for mild-to-moderate psoriasis, enrolling an additional four patients with an improved topical gel formulation [1] Group 1: Trial Results - SGX302 gel therapy was well tolerated, with no drug-related adverse events reported among patients [2] - Improvements were observed in multiple assessment metrics, including Investigator Global Assessment (IGA) and Psoriasis Activity and Severity Index (PASI) [2] - One patient achieved "Almost Clear" status on the IGA, with a PASI score improvement exceeding 50% [3] Group 2: Comparison with Previous Formulation - The outcomes from the gel formulation were similar or improved compared to the previous ointment formulation, attributed to comparable release characteristics and enhanced application ease [4] Group 3: Overall Study Findings - The initial exploratory phase confirmed that SGX302 effectively improves psoriasis lesions and is well tolerated, suggesting a potential non-carcinogenic treatment option [5] - Following the announcement, Soligenix's stock price decreased by 21.05%, trading at $1.21 [5]